Blog
RSS FeedPosted by Michael Wonder on 05 Mar 2024
New treatment option available today for womb cancer
5 March 2024 - A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent ...
Posted by Michael Wonder on 06 Jun 2023
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
6 June 2023 - NICE has published evidence-based recommendations for daratumumab (Darzalex) for use in combination with bortezomib and dexamethasone ...
Posted by Michael Wonder on 11 Nov 2022
Cannabidiol for the treatment of patients with seizures caused by tuberous sclerosis complex
8 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 Mar 2022
Acceptability of manufacturer proposed utility values for NICE cancer medicine appraisals: analysis of manufacturers’ information sources
21 March 2022 - The NICE method guide for technology appraisals encourages medicine manufacturers to use the EuroQol 5 Dimension in ...
Posted by Michael Wonder on 09 Mar 2022
Time to ask companies why they don’t submit to NICE?
9 March 2022 - Companies can choose whether or not to submit to NICE to have their products appraised. ...